Does chronic treatment with a selective HIF PHD inhibitor (GSK360A) improve ventricular performance, remodeling, and vascularity in a rat model of post-myocardial infarction ventricular dysfunction?
In a rat model of post-MI ventricular dysfunction, chronic HIF-PHD inhibition with GSK360A improved ventricular performance and remodeling, highlighting its potential as a therapeutic target for heart failure.
Chronic post-myocardial infarction treatment with a selective HIF PHD inhibitor (GSK360A) exerts systemic and local effects by stabilizing HIF-1 alpha signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These results suggest that HIF-PHD inhibitors may be suitable for the treatment of post-MI remodeling and heart failure.
Bao et al. (2010) studied this question.